

Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Serious eye damage/eye irri-

tation

Category 2A

Respiratory sensitisation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - :

repeated exposure

Category 2 (Kidney)

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

Category 1

GHS label elements

Hazard pictograms







Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.

H334 May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Kidney) through pro-

longed or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and

easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/ at-

tention.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor. P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Chemical name	CAS-No.	Concentration (% w/w)
Cilastatin	81129-83-1	>= 30 -< 60
Imipenem	74431-23-5	>= 30 -< 60
Relebactam	1174020-13-3	>= 10 -< 30

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

Causes serious eye irritation.

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Contact with dust can cause mechanical irritation or drying of

the skin.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)



Imipenem / Cilastatin / Relebactam Formulation

Version 5.2

Revision Date: 2023/09/30

SDS Number: 67739-00029

Date of last issue: 2023/08/09 Date of first issue: 2015/02/27

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbant

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not breathe dust. Do not swallow.

Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Cilastatin	81129-83-1	TWA	5 mg/m3 (OEB 1)	Internal
Imipenem	74431-23-5	TWA	3000 ug/m3 (OEB	Internal
			1)	
	Further information: RSEN, DSEN			
		Wipe limit	100 μg/100 cm2	Internal
Relebactam	1174020-13-	TWA	0.3 mg/m3 (OEB	Internal
	3		2)	

Engineering measures : Use feasible engineering controls to minimize exposure to



Imipenem / Cilastatin / Relebactam Formulation

Version 5.2

Revision Date: 2023/09/30

SDS Number: 67739-00029

Date of last issue: 2023/08/09 Date of first issue: 2015/02/27

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection Material Particulates type

: Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Can react with strong oxidizing agents.

Heat, flames and sparks. Conditions to avoid

Avoid dust formation.

Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of: Inhalation

Skin contact exposure

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cilastatin:

Acute oral toxicity LD50 (Rat): 8,000 mg/kg

LD50 (Mouse): 8,000 mg/kg

Imipenem:

Acute oral toxicity LD50 (Mouse): 10,000 mg/kg

Acute toxicity (other routes of:

administration)

LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous

LD50 (Mouse): 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:

Cilastatin:

Species Rabbit

Result No skin irritation

Relebactam:

Method **EpiDerm**

Result No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Components:

Cilastatin:

Species : Rabbit

Result : Moderate eye irritation

Relebactam:

Result : No eye irritation

Method : Bovine cornea (BCOP)

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:

Exposure routes : Skin contact Remarks : No data available

Exposure routes : Inhalation

Remarks : No data available

Imipenem:

Remarks : May cause sensitisation of susceptible persons by inhalation

of aerosol or dust.

Exposure routes : Skin contact

Remarks : Not classified due to lack of data.

Relebactam:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Dermal

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Cilastatin:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

Result: negative



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Imipenem:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: reverse mutation assay

Result: negative

Test Type: unscheduled DNA synthesis assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Test Type: sister chromatid exchange assay

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intravenous

Result: negative

Relebactam:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cilastatin:

Effects on fertility : Test Type: Fertility/early embryonic development

Application Route: Intravenous

Fertility: LOAEL: 1,000



Imipenem / Cilastatin / Relebactam Formulation

Version 5.2

Revision Date: 2023/09/30

SDS Number: 67739-00029

Date of last issue: 2023/08/09 Date of first issue: 2015/02/27

Symptoms: No adverse effects

Result: No effects on fertility and early embryonic develop-

ment were detected.

Imipenem:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female Application Route: Intravenous

Fertility: LOAEL: 80 mg/kg body weight

Symptoms: No adverse effects, Reduced foetal weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Fertility/early embryonic development

Species: Rat, male and female Application Route: Subcutaneous Fertility: LOAEL: 320 mg/kg body weight

Symptoms: No adverse effects, Reduced foetal weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Effects on foetal develop-

ment

Test Type: Development

Species: Monkey

Application Route: Intravenous

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected., No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Intravenous

Developmental Toxicity: NOAEL: 60 mg/kg body weight

Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Intravenous

Developmental Toxicity: NOAEL: 60 mg/kg body weight

Result: No teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Relebactam:

Effects on fertility : Test Type: Pre-/postnatal development

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 450 mg/kg body weight



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal injection

Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal injection

Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight

Result: No effects on foetal development

Test Type: Development

Species: Rat

Application Route: Intravenous

Developmental Toxicity: NOAEL: >= 450 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Development

Species: Rabbit

Application Route: Intravenous

Developmental Toxicity: NOAEL: 450 mg/kg body weight

Result: No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Kidney) through prolonged or repeated exposure.

Components:

Relebactam:

Target Organs : Kidney

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cilastatin:

Species : Rat

NOAEL : >= 500 mg/kg
Application Route : Intravenous
Exposure time : 90 Days

Remarks : No significant adverse effects were reported

Species : Monkey NOAEL : >= 500 mg/kg



Imipenem / Cilastatin / Relebactam Formulation

Date of last issue: 2023/08/09 Version Revision Date: SDS Number: 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Application Route Intravenous Exposure time 5 Weeks

Remarks No significant adverse effects were reported

Imipenem:

Species Monkey 60 mg/kg **NOAEL** LOAEL 150 mg/kg Application Route Intravenous Exposure time 6 Months **Target Organs** Kidney

Species Monkey NOAEL 120 mg/kg Application Route Subcutaneous Exposure time 6 Months

Remarks No significant adverse effects were reported

Species Rat 180 mg/kg NOAEL Application Route Intravenous Exposure time 6 Months

Remarks No significant adverse effects were reported

Species Rabbit LOAEL 150 mg/kg Intravenous Application Route **Target Organs** Kidney

Relebactam:

Species Rat, female 150 mg/kg NOAEL Application Route : Intravenous

Exposure time 30 d

Species Rat, male NOAEL 450 mg/kg Application Route Intravenous

30 d Exposure time

Species Monkey NOAEL 25 mg/kg Intravenous Application Route 30 d Exposure time

Target Organs Kidney

Species Monkey **NOAEL** 37.5 mg/kg **Application Route** Intravenous



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Exposure time : 30 d

Species : Monkey
NOAEL : 50 mg/kg
LOAEL : 150 mg/kg
Application Route : Intravenous
Exposure time : 3 Months
Target Organs : Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Imipenem:

Inhalation : Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension,

Dizziness, Drowsiness, Convulsions, pruritis, Rash

Remarks: May cause sensitisation of susceptible persons by

inhalation of aerosol or dust.

Relebactam:

Skin contact : Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain,

insomnia, Nausea, sore throat, Vertigo

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cilastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 99 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena flos-aquae): > 99 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 99

ng/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 99 mg/l



Imipenem / Cilastatin / Relebactam Formulation

Version 5.2

Revision Date: 2023/09/30

SDS Number: 67739-00029

Date of last issue: 2023/08/09 Date of first issue: 2015/02/27

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 99

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

EC10 (Pimephales promelas (fathead minnow)): > 9.9 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

EC10 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Imipenem:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 78 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 74

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 74

mg/l

100

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Toxicity to daphnia and other : aquatic invertebrates (Chron-

aquatic invertebrates (Crit

ic toxicity)

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 11 mg/l

M-Factor (Chronic aquatic

toxicity)

Toxicity to microorganisms : EC50: > 1,000 mg/l

10

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Relebactam:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 12

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 2.7 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 96.3 mg/l



Imipenem / Cilastatin / Relebactam Formulation

Version 5.2

Revision Date: 2023/09/30

SDS Number: 67739-00029

Date of last issue: 2023/08/09 Date of first issue: 2015/02/27

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cilastatin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 27 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Imipenem:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 29 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Relebactam:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 11.3 % Exposure time: 28 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Cilastatin:

Partition coefficient: n-

octanol/water

log Pow: -3.53

Imipenem:

Partition coefficient: n-

: log Pow: < -1

octanol/water

Relebactam:

Partition coefficient: n-

log Pow: < -2

octanol/water

Mobility in soil

Components:

Cilastatin:

Distribution among environ-

mental compartments

: log Koc: 2.3



Imipenem / Cilastatin / Relebactam Formulation

Date of last issue: 2023/08/09 Version Revision Date: SDS Number: 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

Relebactam:

Distribution among environmental compartments

: log Koc: 2.3

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number UN 3077

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Imipenem)

Class 9 Packing group Ш 9 Labels Environmentally hazardous yes

IATA-DGR

UN/ID No. UN 3077

Proper shipping name Environmentally hazardous substance, solid, n.o.s.

(Imipenem)

Class 9 Packing group Ш

Labels Miscellaneous 956

Packing instruction (cargo

aircraft)

Packing instruction (passen-

ger aircraft)

956

Environmentally hazardous yes

IMDG-Code

UN number UN 3077

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

> N.O.S. (Imipenem)

Class 9 Packing group Ш Labels 9



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 5.2 2023/09/30 67739-00029 Date of first issue: 2015/02/27

EmS Code : F-A, S-F Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mix-

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and : Not applicable

control, Annex I

Type of hazardous materials subject to distribution and : Not applicable

control, Annex II

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined



Imipenem / Cilastatin / Relebactam Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/08/09 2023/09/30 67739-00029 Date of first issue: 2015/02/27 5.2

16. OTHER INFORMATION

2023/09/30 **Revision Date**

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.



Imipenem / Cilastatin / Relebactam Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 2023/08/09

 5.2
 2023/09/30
 67739-00029
 Date of first issue: 2015/02/27

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN